Alterity Therapeutics (NASDAQ:ATHE) Trading Down 3.8% – What’s Next?

Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE)’s share price fell 3.8% on Friday . The stock traded as low as $3.27 and last traded at $3.29. 17,147 shares traded hands during trading, an increase of 34% from the average session volume of 12,767 shares. The stock had previously closed at $3.42.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Alterity Therapeutics in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Alterity Therapeutics currently has an average rating of “Hold” and an average target price of $12.00.

Alterity Therapeutics Trading Down 3.8%

The firm’s fifty day simple moving average is $3.98 and its two-hundred day simple moving average is $4.44.

Institutional Investors Weigh In On Alterity Therapeutics

A number of institutional investors have recently bought and sold shares of the business. Greenleaf Trust bought a new stake in Alterity Therapeutics during the second quarter valued at about $70,000. Citadel Advisors LLC purchased a new stake in shares of Alterity Therapeutics during the third quarter worth about $83,000. HB Wealth Management LLC purchased a new stake in shares of Alterity Therapeutics during the third quarter worth about $220,000. Finally, Twin Lakes Capital Management LLC raised its stake in Alterity Therapeutics by 2,250.3% during the 3rd quarter. Twin Lakes Capital Management LLC now owns 139,258 shares of the company’s stock valued at $524,000 after purchasing an additional 133,333 shares during the period. Hedge funds and other institutional investors own 2.14% of the company’s stock.

About Alterity Therapeutics

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia. The company’s lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson’s disease.